Ropes & Gray advised Kailera Therapeutics, Inc. and its investors on the establishment of the company, its $400 million Series A financing, and the worldwide (ex-China) licensing by the company of a portfolio of clinical-stage metabolic disease assets from Hengrui Pharmaceuticals, a leading Chinese pharmaceutical company.Ā Atlas Venture, Bain Capital Life Sciences, and RTW Investments led the Series A financing, with participation from Lyra Capital.
Kailera is a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions.Ā The company is based in Waltham, Massachusetts, and San Diego, California.
The Ropes & Gray team was led by New York-based corporate partnerĀ Arthur Mok, San Francisco-based licensing partnerĀ Geoffrey Lin, Boston-based corporate counselĀ Ray GrantĀ and Boston-based licensing associateĀ Evan Tallmadge.Ā Ā The team alsoĀ included Singapore-based regulatory partnerĀ Katherine Wang, Washington D.C.-based national security partnerĀ Ama Adams, Washington D.C.-based antitrust partnerĀ Jonathan Klarfeld, Boston-based tax partnersĀ Amanda HoltĀ andĀ David Saltzman, andĀ Boston-basedĀ executive compensation & employee benefits partnerĀ Renata Ferrari.
